Ana Juanes1, Noe Garin1,2, Maria Antonia Mangues1,3, Sergio Herrera4, Mireia Puig4, Maria Jose Faus5, Maria Isabel Baena5. 1. Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 2. Instituto de Salud Carlos III, Centro de Investigacin Biomdica en Red de Salud Mental, CIBERSAM, Madrid, Spain. 3. CIBER de Bioingeniera, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. 4. Emergency Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 5. Pharmaceutical care Research Group, Universidad de Granada, Granada, Spain.
Abstract
BACKGROUND: The resolution of potential drug-related problems is a priority of pharmaceutical care programmes. OBJECTIVES: To assess the clinical impact on drug-related negative outcomes of a pharmaceutical care programme focusing on the resolution of potential drug-related problems, initiated in the emergency department for patients with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD). METHODS: Controlled trials, in which older adults (≥65 years) receiving four or more medications admitted to the emergency department for ≥12 hours for worsening of HF and/or COPD were randomised (1:1) to either a pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department (intervention group (IG)) or standard care (control group). Comparisons between the groups were made for the proportion of patients with drug-related negative outcomes, number of drug-related negative outcomes per patient, mean stay, patients readmitted within 180 days and 180-day mortality. RESULTS: 118 patients were included, 59 in each group. Fewer patients in the IG had drug-related negative outcomes (37 (62.7%) vs 47 (79.7%) in the control group (p=0.042)). Fewer drug-related negative outcomes per patient occurred in the IG (56 (0.95 per patient) vs 85 (1.44 per patient) in the control group (p=0.01)). The mean stay was similar between groups (194.7 hours in the IG vs 242.5 hours in the control group (p=0.186)). No difference in revisits within 180 days was found (32 (54.24%) in the IG vs 22 (37.3%) in the control group (p=0.065)). 180-Day mortality was detected in 11 (18.6%) patients in the IG compared with 13 (22%) in the control group (p=0.647). CONCLUSION: A pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department has a favourable clinical impact, as it reduces the number and prevalence of drug-related negative outcomes. No difference was found in other outcome variables.Trial registration number NCT02368548.
BACKGROUND: The resolution of potential drug-related problems is a priority of pharmaceutical care programmes. OBJECTIVES: To assess the clinical impact on drug-related negative outcomes of a pharmaceutical care programme focusing on the resolution of potential drug-related problems, initiated in the emergency department for patients with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD). METHODS: Controlled trials, in which older adults (≥65 years) receiving four or more medications admitted to the emergency department for ≥12 hours for worsening of HF and/or COPD were randomised (1:1) to either a pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department (intervention group (IG)) or standard care (control group). Comparisons between the groups were made for the proportion of patients with drug-related negative outcomes, number of drug-related negative outcomes per patient, mean stay, patients readmitted within 180 days and 180-day mortality. RESULTS: 118 patients were included, 59 in each group. Fewer patients in the IG had drug-related negative outcomes (37 (62.7%) vs 47 (79.7%) in the control group (p=0.042)). Fewer drug-related negative outcomes per patient occurred in the IG (56 (0.95 per patient) vs 85 (1.44 per patient) in the control group (p=0.01)). The mean stay was similar between groups (194.7 hours in the IG vs 242.5 hours in the control group (p=0.186)). No difference in revisits within 180 days was found (32 (54.24%) in the IG vs 22 (37.3%) in the control group (p=0.065)). 180-Day mortality was detected in 11 (18.6%) patients in the IG compared with 13 (22%) in the control group (p=0.647). CONCLUSION: A pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department has a favourable clinical impact, as it reduces the number and prevalence of drug-related negative outcomes. No difference was found in other outcome variables.Trial registration number NCT02368548.
Authors: Asad E Patanwala; Arthur B Sanders; Michael C Thomas; Nicole M Acquisto; Kyle A Weant; Stephanie N Baker; Erica M Merritt; Brian L Erstad Journal: Ann Emerg Med Date: 2012-01-05 Impact factor: 5.721
Authors: C Berga Culleré; M Q Gorgas Torner; J Altimiras Ruiz; M Tuset Creus; M Besalduch Martín; M Capdevila Sunyer; M Torres Gubert; M T Casajoana Cortinas; E Baró Sabaté; J R Fernández Solà; A Moron i Besolí; E Odena Estradé; J Serrais Benavente; M T Vitales Farrero; C Codina Jané Journal: Farm Hosp Date: 2009 Nov-Dec
Authors: Patrice Queneau; Bernard Bannwarth; Françoise Carpentier; Jean-Michel Guliana; Jacques Bouget; Béatrice Trombert; Xavier Leverve; Frédéric Lapostolle; Stephen W Borron; Frédéric Adnet Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Paloma Gastelurrutia; Shalom Isaac Benrimoj; José Espejo; Laura Tuneu; M Antonia Mangues; Antoni Bayes-Genis Journal: J Card Fail Date: 2010-12-24 Impact factor: 5.712
Authors: Jeffrey M Rothschild; William Churchill; Abbie Erickson; Kristin Munz; Jeremiah D Schuur; Claudia A Salzberg; Daniel Lewinski; Rita Shane; Roshanak Aazami; John Patka; Rondell Jaggers; Aaron Steffenhagen; Steve Rough; David W Bates Journal: Ann Emerg Med Date: 2009-12-11 Impact factor: 5.721
Authors: Bruce E Koehler; Kathleen M Richter; Liz Youngblood; Brian A Cohen; Irving D Prengler; Dunlei Cheng; Andrew L Masica Journal: J Hosp Med Date: 2009-04 Impact factor: 2.960
Authors: E Delgado-Silveira; M Vélez-Díaz-Pallarés; M Muñoz-García; A Correa-Pérez; A M Álvarez-Díaz; A J Cruz-Jentoft Journal: Eur Geriatr Med Date: 2021-05-07 Impact factor: 1.710
Authors: Jesus Ruiz Ramos; Laura Gras-Martin; Ana María Juanes Borrego; Marta Blazquez-Andion; Mireia Puig Campmany; Maria Antonia Mangues-Bafalluy Journal: J Pharm Technol Date: 2021-04-30
Authors: Emma J Dennett; Sadia Janjua; Elizabeth Stovold; Samantha L Harrison; Melissa J McDonnell; Anne E Holland Journal: Cochrane Database Syst Rev Date: 2021-07-26